Dr. Michael R. HodgesDr. Michael R. Hodges has 24 years of biopharmaceutical development experience in both large pharmaceutical and biotechnology companies across a broad range of therapeutic areas, including infectious disease, oncology, respiratory and dyslipidemia. He is currently CMO at Amplyx Pharmaceuticals and recently served as the Vice President of Drug Development and Chief Medical Officer for Santaris A/S, an RNA therapeutic platform company developing drugs for cancer, infectious diseases and metabolic diseases. Santaris was acquired by Hoffmann-La Roche AG in September 2014. Prior to Santaris, Michael was the Chief Medical Officer for Altair Inc., a respiratory RNA therapeutics platform company, developing inhaled drugs for asthma and other pulmonary inflammatory diseases. He served in Pfizer Global Research and Development in Sandwich UK, Groton CT USA, New London CT USA and La Jolla CA USA, for 17 years and his career has included working on the development programs for the following commercial products: Vfend®, Eraxis®, Diflucan®, Zithromax®, Tarceva®, Inlyta® and Viagra®. Before joining the pharmaceutical industry, Michael practiced internal medicine in the United Kingdom. Michael received his undergraduate degree in Pharmacology from Kings College, and medical degree at the Westminster Medical School, University of London, UK.
Dr. Drew WeissmanDr. Weissman, is a professor of Medicine at the Perelman School of Medicine, University of Pennsylvania with over 100 publications and patents. He received his graduate degrees from Boston University School of Medicine. Dr. Weissman co-discovered the ability of modified nucleosides in RNA to suppress activation of innate immune sensors and increase the translation of mRNA containing certain modified nucleosides. Dr. Weissman's laboratory focuses on the study of RNA and innate immune system biology and the application of these findings to vaccine research, protein therapeutics, and gene therapy. He is also an Attending Physician at the Philadelphia Veterans Administration Medical Center, a member of The American Association of Immunologists, and a member of the American Federation for Clinical Research.
Dr. Michael R. Hodges has 24 years of biopharmaceutical development experience in both large pharmaceutical and biotechnology companies across a broad range of therapeutic areas, including infectious disease, oncology, respiratory and dyslipidemia.
Dr. Weissman, is a professor of Medicine at the Perelman School of Medicine, University of Pennsylvania with over 100 publications and patents.
March 27, 2020
Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System
March 11, 2020
Arcturus Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results
March 4, 2020
Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology